Cadila gets USFDA nod for Emtricitabine & TDF tablets

Zydus Cadila today informed the bourses that it has received a final approval from US Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate (TDF) Tablets, 200 mg/300 mg and tentative approval for the strength of 100 mg/ISO mg, 133 mg/200 mg and 167 mg/250 mg, of the same drug.

In order to curb HIV infection, this product is to be used with other HIV medications. It helps to decrease the amount of HIV in the body so that the immune system can work better. The product would be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group is now having 281 approvals and has so far, filed over 386 ANDAs since the commencement of the filing process.

Cadila's FY19 revenue mix comprised US formulations (50 per cent), India formulations (29 per cent), EMB formulations (six per cent), Animal Health (four per cent), Wellness (four per cent), API (three per cent), Alliances (two per cent) and Europe Formulations (two per cent).

Today, the stock of Cadila Healthcare opened at Rs 261.25 per share and made an intraday high of Rs 263.10 on BSE. At 11.44 am, the stock was trading nearly at Rs 260.80 on BSE.